What's happened
Kalshi has launched biotech contracts tied to drug trial outcomes in partnership with AppliedXL, enabling investors to bet on regulatory decisions. The move aims to offer continuously updated probabilities from trial data, while regulators warn of potential market manipulation and insider trading. The pilot includes safety safeguards and a focus on disclosure.
What's behind the headline?
Context and implications
- Kalshi has introduced a new class of biotech contracts that reflect the probability of drug approvals, aiming to expose information locked inside trial data.
- This moves the market closer to real-time assessment of trial progress, potentially shifting investor behavior and company signaling.
- Critics warn of incentives to influence recruitment or accelerate disclosures, while Kalshi points to verification steps and enrollment-based listing to mitigate issues.
What to watch
- Regulatory feedback from the FDA and SEC could shape how these markets evolve.
- The balance between open data and patient safety will determine whether more contracts appear in related areas.
- Market participants will reassess risk if disclosure timelines shorten or become more granular.
How we got here
Kalshi, a public prediction market operator, is expanding into biotech with new contracts that hinge on drug trial outcomes. The launch follows earlier moves into flight-delay bets and reflects a broader push to bring transparent data to opaque clinical-trial processes. Regulators have expressed concerns about manipulation, while Kalshi emphasizes compliance and safeguards.
Our analysis
Bloomberg reports that Kalshi is launching 13 new biotech contracts with AppliedXL, assessing whether US regulators will approve medicines from Sanofi and Gilead. The Guardian notes the firm’s emphasis on transparency and safeguards against insider trading, while Bloomberg also highlights broader pilot programs, including flight-disruption bets. The Guardian quotes Kalshi CEO Tarek Mansour on the aim of revealing previously opaque trial information.
Go deeper
- Will regulators tighten rules on prediction markets tied to drug approvals?
- How might real-time trial probabilities affect investment decisions?
- What safeguards exist to prevent manipulation or misuse?
More on these topics
-
Kalshi - American prediction market platform
Kalshi Inc. is a prediction market platform based in Manhattan, New York City, that launched in July 2021. The platform is used primarily for sports betting, which constitutes more than 90% of site activity and 89% of revenue in 2025. Analysts describe activity on the platform as "heavily tied to the sports calendar". Individuals can place bets on other future outcomes, including economic indicators, weather patterns, awards, political and legislative outcomes, and military conflicts. The site has been involved in several controversies and lawsuits regarding the legality of its sports and election markets, the ethics of allowing wagers on sensitive geopolitical issues, and insider trading involving politicians. Concerns over election integrity and declining public trust in the democratic process caused by election betting have been raised by consumer advocacy groups and politicians. As a result, the United States Senate banned its senators and their staff from betting on prediction markets such as Kalshi in May 2026. According to the site, there are 2.9 unprofitable users for each profitable one. Scholars have challenged whether Kalshi efficiently and accurately aggregates information...